Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability

被引：3
作者：
Prentice, HG
机构：
[1] UCL Royal Free & Univ Coll, Sch Med, London W1G 6BW, England
[2] London Clin, Dept Haematol, London W1G 6BW, England
来源：
SUPPORTIVE CARE IN CANCER | 2003年 / 11卷 / 08期
关键词：
granisetron; nausea; vomiting; anti-emetic; 5-HT3 receptor antagonist; HIGH-DOSE CHEMOTHERAPY; STEM-CELL TRANSPLANTATION; BODY IRRADIATION PRIOR; ANTIEMETIC EFFICACY; ORAL GRANISETRON; PREVENTION; ONDANSETRON; SAFETY; DEXAMETHASONE; PROPHYLAXIS;
D O I：
10.1007/s00520-003-0480-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cancer patients undergoing bone marrow transplantation (BMT) experience severe nausea and vomiting associated with high-dose chemotherapy agents; these emetic symptoms are compounded by total body irradiation used in many conditioning regimens. This paper reviews clinical experience with the 5-HT3 receptor antagonist granisetron, both as a single agent and in combination with other anti-emetics, in patients undergoing BMT and peripheral blood stem cell transplantation (PBSCT). Clinical studies demonstrate the efficacy (47-61% with no vomiting and no worse than mild nausea) and tolerability of granisetron. Its long half-life and duration of action may be responsible for its effective 24 h control of nausea and vomiting in BMT patients.
引用
收藏
页码：501 / 508
页数：8
相关论文
共 31 条
[1]   Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation [J].
Abang, AM ;
Takemoto, MH ;
Pham, T ;
Mandanas, RA ;
Roy, V ;
Selby, GB ;
Carter, TH .
ANTI-CANCER DRUGS, 2000, 11 (02) :137-142
[2]   Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation [J].
Abbott, B ;
Ippoliti, C ;
Hecth, D ;
Bruton, J ;
Whaley, B ;
Champlin, R .
BONE MARROW TRANSPLANTATION, 2000, 25 (12) :1279-1283
[3]   Antiemetic efficacy of granisetron pins dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation [J].
Abbott, B ;
Ippoliti, C ;
Bruton, J ;
Neumann, J ;
Whaley, R ;
Champlin, R .
BONE MARROW TRANSPLANTATION, 1999, 23 (03) :265-269
[4]   Outpatient total body irradiation prior to bone marrow transplantation in pediatric patients: a feasibility analysis [J].
Applegate, GL ;
Mittal, BB ;
Kletzel, M ;
Morgan, E ;
Johnson, P ;
Danner, K ;
Marymont, MH .
BONE MARROW TRANSPLANTATION, 1998, 21 (07) :651-652
[5]   Total body irradiation prior to bone marrow transplantation: Efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis [J].
Belkacemi, Y ;
Ozsahin, M ;
Pene, F ;
Rio, B ;
Sutton, L ;
Laporte, JP ;
Touboul, E ;
Gorin, NC ;
Laugier, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (01) :77-82
[6]  
BLOOMER JC, 1994, BR J CLIN PHARM, V38, P273
[7]   Granisetron: relating pharmacology to clinical efficacy [J].
Blower, PR .
SUPPORTIVE CARE IN CANCER, 2003, 11 (02) :93-100
[8]   Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation [J].
Bubalo, Y ;
Seelig, F ;
Karbowicz, S ;
Maziarz, RT .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (08) :439-445
[9]   Outcomes of recipients of both bone marrow and solid organ transplants - A review [J].
Dey, B ;
Sykes, M ;
Spitzer, TR .
MEDICINE, 1998, 77 (05) :355-369
[10]  
FOXGEIMAN M, 1999, P ASCO, V18, pA592
1234